16:50 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Adaptimmune reports Phase I safety data for TCR therapy

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported safety data from eight evaluable patients receiving 90-100 million cells of its MAGE-A10 SPEAR T cell therapy in two open-label Phase I trials to treat cancer. The data were presented...
19:25 , Sep 8, 2017 |  BC Week In Review  |  Company News

GSK exercises option for Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune was preparing for a pivotal trial...
00:23 , Sep 8, 2017 |  BC Extra  |  Company News

GSK nabs Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $0.81 (12%) to $7.55 Thursday after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR-like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the company...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

MAGE-A10 SPEAR T-cell therapy: Phase I started

Adaptimmune began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV MAGE A10 TCR in up to 12 patients with an HLA-A*201 or HLA-A*206 allele and tumors expressing MAGEA10. Adaptimmune Therapeutics plc (NASDAQ:ADAP), Abingdon, U.K.  Product:...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Adaptimmune Therapeutics, University of Texas MD Anderson Cancer Center deal

Adaptimmune and MD Anderson partnered to develop T cell receptor (TCR) cancer therapeutics using Adaptimmune’s Specific Peptide Enhanced Affinity Receptor (SPEAR) technology. The partnership will initially focus on compounds against melanoma-associated antigen A10...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

MAGE A10 TCR: Phase I/II started

Adaptimmune began an open-label, dose-escalation, international Phase I/II trial to evaluate IV MAGE A10 TCR in up to 32 patients with the HLA-A*0201 and HLA-A*0206 alleles and NSCLC positive for MAGEA10. Adaptimmune Therapeutics plc (NASDAQ:ADAP),...